NCT03734575 is a NA clinical trial of ClariCore System in Prostate Cancer, sponsored by Precision Biopsy, Inc..

Who is sponsoring NCT03734575?

NCT03734575 is sponsored by Precision Biopsy, Inc..

What drugs are being tested in NCT03734575?

Interventions in NCT03734575: ClariCore System.

What condition does NCT03734575 study?

NCT03734575 studies Prostate Cancer.

Is NCT03734575 still recruiting?

NCT03734575 is currently suspended. Last updated 11 July 2019.

Last reviewed 2019-07-11 · How we verify

NCT03734575

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ClariCore System Used in Transperineal Prostate Biopsy

Suspended NA Last updated 11 July 2019

What this trial tests

NA trial testing ClariCore System in Prostate Cancer in 60 participants. Suspended.

Timeline

10 October 2018

Primary endpoint
9 July 2019

9 July 2019

Quick facts

Lead sponsor	Precision Biopsy, Inc.
Phase	NA
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	10 October 2018
Primary completion	9 July 2019
Estimated completion	9 July 2019
Sites	2 locations across United States

Drugs / interventions tested

ClariCore System

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Precision Biopsy, Inc.

Who can join

Eligibility, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of this study is to acquire ultrasound images, spectral data and prostate tissue biopsy cores using the ClariCore System via a transperineal approach.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03734575 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Precision Biopsy, Inc.
Last refreshed: 11 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03734575.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing